News

Eisai's new research unit taps Genomics for analysis support

Eisai has added to its genomics capabilities. The latest move sees the Japanese drugmaker's nascent Integrated Human Genomics (IHGx) Research Unit team up with Genomics plc, an Oxford University spinout founded in response to the United Kingdom's 100,000 Genomes Project.

Potency-prediction software helps Schrödinger land $120M Sanofi deal

Schrödinger has racked up another tech-validating deal. Having seen the biotech it helped to found rake in $43 million from Pfizer and others last month, the computational drug design veteran has now struck a $120 million discovery deal with Sanofi.

Genentech begins search for bioinformatics chief after Gentleman leaves for 23andMe

The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.

23andMe-style sequencing project taps Facebook in pursuit of 20,000 participants

Researchers at the University of Michigan are trying to speed toward their goal of enrolling 20,000 people in a study by piggybacking onto Facebook's vast social network. And the genotypic and phenotypic data gathering project is off to a brisk start, with more than 2,000 people signing up in the days after its public launch.

Medidata lands deals with Accenture and Biorasi

Medidata has bolstered its books with two new deals. Accenture is tightening the ties between its R&D service offering and Medidata's Clinical Cloud and Rave EDC system.

Celgene, Genentech back clinical trial enrollment challenge

Celgene and Genentech are funding a clinical trial innovation prize focused on doubling the rate of participation in studies of cancer drugs. The project is challenging the crowd to submit ideas and evidence of their effectiveness in return for the chance to land a piece of the $75,000 prize kitty.

Genome Canada makes $24M pivot to bolster bioinformatics capabilities

Genome Canada is aiming to retool the country's genomics infrastructure by plowing $12.2 million in federal funding and a similar amount from other sources into 10 research centers.

NIH backs database of rare pediatric genetic disorders

Cincinnati Children's Hospital Medical Center has received $2.2 million from the National Institutes of Health (NIH) to track children who have rare genetic disorders.

Emerging markets tipped to push drug safety software market past $150M

Analysts at MarketsandMarkets have looked into their crystal ball and come up with a forecast of the pharmacovigilance and drug safety software sector. The authors predict the value of the market will top $150 million by 2019, with Asia and Latin America tipped to be the driving forces behind growth over the next few years.

George Church backs online platform for open sharing of personal data

Harvard geneticist George Church has backed Open Humans, an online platform that asks people to openly share their genomes and other personal data. The idea is to marry the underlying principles of the open-source and quantified-self movements to make more data available to more researchers.

Committee clips the wings of Europe's controversial $1B brain project

An independent committee set up to probe a dispute over Europe's $1 billion Human Brain Project (HBP) has sided with critics of the initiative. The outcome leaves the fate of HBP and its ambitious and much-criticized plan to simulate the brain using a supercomputer in doubt.

100,000 Genomes Project taps Big Pharma dream team for data crunching skills

The United Kingdom has wasted no time getting industry involved with its 100,000 Genomes Project. With just 3% of the sequencing work done, Genomics England has enlisted the help of a who's who of Big Pharma companies to pore over the data in search of new avenues for drug discovery.

Amgen's deCODE lays marker for future of genomics-driven drug discovery

Amgen's deCODE Genetics has released a glimpse of a future in which population-scale genome sequencing forms the basis of drug discovery programs. And while the initiative still has some technical shortcomings and has yet to prove to the outside world it is worth $415 million, it nonetheless sparked excitement in the genomics community.

India crowdsources whistleblowing with website, mobile app

India has given consumers a way to complain about the availability or pricing of drugs. By providing an online portal and mobile app through which consumers can vent their grievances, Indian authorities are trying to turn the country's vast population into a disaggregated army of whistleblowers.

Big Pharma nervously eying Apple and Google's healthcare pitches

The Financial Times has taken a look at the implications of Apple and Google's ever-growing interest in healthcare and life sciences.

FDA under pressure to establish staff social media policy

Having faced years of criticism for its failure to publish guidelines on how the industry can use social media, the FDA is now being chastised by the advocacy group Union of Concerned Scientists over its lack of a policy for its staff.

Cloud Pharmaceuticals allies with U. of Florida to advance in silico pipeline

Cloud Pharmaceuticals has taken the next step in its push to create a pipeline of drugs discovered using a computer-based design process, hooking up with the University of Florida to transition its computer-discovered drugs into traditional preclinical research.

AstraZeneca taps Assay Depot to create preclinical service hub

The list of IT vendors and service providers that have yet to strike a deal with AstraZeneca in 2015 keeps getting shorter. Assay Depot is the latest name to cross of the list after the scientific services marketplace agreed to create a private research e-commerce platform for AstraZeneca.

Nimbus bags $43M from Big Pharma VCs to test computer-designed drugs

Nimbus Therapeutics is ready to see how the compounds it discovered with the help of Schrödinger's computational chemistry tools fare in the clinic. And the VC units of Eli Lilly, GlaxoSmithKline and Pfizer want to find out, too, prompting each to chip in to Nimbus' $43 million Series B round.

UCB to host epilepsy digital tool hackathon

UCB is hosting a hackathon focused on developing new tools to improve the day-to-day lives of people with epilepsy and their families, PMLiVE reports.